These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 30145072

  • 1. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 2. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 3. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
    Chou A, Toon CW, Clarkson A, Sheen A, Sioson L, Gill AJ.
    Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
    [Abstract] [Full Text] [Related]

  • 4. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [Abstract] [Full Text] [Related]

  • 5. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T.
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [Abstract] [Full Text] [Related]

  • 6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 May 01; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 9. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 10. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan 01; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
    Habougit C, Trombert-Paviot B, Karpathiou G, Casteillo F, Bayle-Bleuez S, Fournel P, Vergnon JM, Tiffet O, Péoc'h M, Forest F.
    Virchows Arch; 2017 Jun 01; 470(6):639-646. PubMed ID: 28349237
    [Abstract] [Full Text] [Related]

  • 13. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L, Duregon E, Vatrano S, Izzo S, Giorcelli J, Rondón-Lagos M, Ascoli V, Ruffini E, Ventura L, Volante M, Papotti M, Scagliotti GV.
    J Thorac Oncol; 2016 Nov 01; 11(11):2006-2017. PubMed ID: 27422796
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F, Vimercati L, Fortarezza F, Marzullo A, Pennella A, Cavone D, Punzi A, Caporusso C, d'Amati A, Lettini T, Serio G.
    Diagn Pathol; 2021 Jul 22; 16(1):64. PubMed ID: 34294087
    [Abstract] [Full Text] [Related]

  • 15. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Pathol Int; 2016 Oct 22; 66(10):563-570. PubMed ID: 27614970
    [Abstract] [Full Text] [Related]

  • 16. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 22; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 17. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN, Baldavira CM, Balancin M, Ab'Saber A, Takagaki T, Capelozzi VL.
    Front Immunol; 2023 Feb 22; 14():1268927. PubMed ID: 37901248
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
    Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M, Che G.
    Oncotarget; 2017 Jul 11; 8(28):46425-46435. PubMed ID: 28507279
    [Abstract] [Full Text] [Related]

  • 19. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 11; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 20. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb 11; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.